Rectify Pharmaceuticals Presents Discovery of Clinical Candidate RTY-406, a Novel Disease-Modifying Therapy for the Treatment of PSC at ACS Fall 2026 Meeting

Presentation highlights the discovery and characterization of RTY-406, an oral, once-daily investigational therapy targeting ...
Yahoo Finance

Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and ...
Seeking Alpha

RTY - Russell 2000 Index

A high-level overview of Russell 2000 Index (RTY) stock. View (RTY) real-time stock price, chart, news, analysis, analyst reviews and more.
manilatimes

Rectify Pharmaceuticals Presents Discovery of Clinical Candidate RTY-406, a Novel Disease-Modifying Therapy for the Treatment of PSC at ACS Fall 2026 Meeting

Presentation highlights the discovery and characterization of RTY-406, an oral, once-daily investigational therapy targeting the underlying drivers of disease in Primary Sclerosing Cholangitis (PSC) ...
manilatimes

Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis

RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of mechanism in non-human primates RTY-406 is in Phase 1 ...